The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 9, 2022. Its latest SEC filing is a EFFECT from Jul 17, 2023.
10-Q for Q3 FY2022, filed Nov 9, 2022
The sections below describe the company as of the FY2021 annual report.
Sells Rubraca, an anti-cancer drug, and develops other cancer medicines for patients with ovarian, prostate and other cancers.
10-K for FY2021, filed Feb 24, 2022We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States…View ↗
Rubraca® is an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”) marketed in the United States for two indications…View ↗
FAP-2286 is our initial product candidate to emerge from our targeted radionuclide therapy collaboration with 3B Pharmaceuticals GmbH…View ↗
Lucitanib, our product candidate currently in clinical development, is an investigational, oral, potent angiogenesis inhibitor which…View ↗
Sells Rubraca to specialty distributors and pharmacies; customers typically receive the product on delivery, and payment terms range from 30 to 60 days.
10-K for FY2021, filed Feb 24, 2022We are currently approved to sell Rubraca in the United States and Europe markets. We distribute our product principally through a limited…View ↗
Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our…View ↗
Discounts and Fees. Our payment terms range from 30 to 60 days. Specialty distributors and specialty pharmacies are offered various forms…View ↗
$148.8M
10-K for FY2021, filed Feb 23, 2022
$148.8M ↗
Specialty distributors and specialty pharmacies buy Rubraca and sell it on to patients and health care providers. The company also works with payors and other third parties on rebates, discounts and chargebacks.
10-K for FY2021, filed Feb 24, 2022We are currently approved to sell Rubraca in the U.S. and Europe markets. We distribute our product principally through a limited number of…View ↗
GPO and Payor Rebates. We contract with various private payor organizations and group purchasing organizations (“GPO”), primarily insurance…View ↗
Chargebacks. Chargebacks are discounts that occur when contracted customers, which currently consist primarily of GPOs, Public Health…View ↗
No. It lost $264.5M in FY2021.
10-K for FY2021, filed Feb 23, 2022
−$225.8MView ↗
10-K for FY2021, filed Feb 23, 2022
−$264.5MView ↗
10-K for FY2021, filed Feb 23, 2022
−$196.4MView ↗
10-Q for Q3 FY2022, filed Nov 9, 2022
−$56MView ↗
8-K, filed Jul 11, 2023
On July 10, 2023 (the “Effective Date”), the Debtors filed a Notice of Effective Date with the Court and the Plan became effective in…View ↗
8-K, filed Jun 2, 2023
On May 26, 2023, the Company received a complete response letter from the United States Food and Drug Administration (the “FDA”) in which…View ↗
8-K, filed May 1, 2023
As previously disclosed, on April 5, 2023, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with…View ↗
8-K, filed Apr 14, 2023
As previously disclosed, on December 11, 2022, the Company entered into a purchase and assignment agreement (as amended, the “Purchase and…View ↗
Grew. Revenue grew 2.7x in 4 years, from $55.5M in FY2017 to $148.8M in FY2021, about 28% a year.
Added prostate cancer
The latest report describes Rubraca as also approved in the United States for certain patients with metastatic prostate cancer, while the older report described its marketed indications as ovarian cancer treatment and maintenance.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Feb 24, 2022Our product Rubraca® (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is marketed in the United States…View ↗
Lucitanib development narrowed
The older report planned studies combining lucitanib with nivolumab and Rubraca; the latest report describes the nivolumab combination study and says Clovis would not pursue further development in gynecologic cancers.
10-K for FY2018, filed Feb 28, 2019 10-K for FY2021, filed Feb 24, 2022Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3…View ↗
Lucitanib, our product candidate currently in clinical development, is an investigational, oral, potent angiogenesis inhibitor which…View ↗
Competes with AstraZeneca UK, GlaxoSmithKline, Pfizer, AbbVie, BeiGene, Merck &, and Janssen Pharmaceuticals
10-K for FY2021, filed Feb 24, 2022Lynparza®/olaparib (AstraZeneca UK Limited) was the first PARP inhibitor to market and has been approved in the US in the following…View ↗
Loading...
